TITLE

Cancer News Round-up

PUB. DATE
September 2004
SOURCE
PharmaWatch: Monthly Review;September 2004, Vol. 3 Issue 9, p4
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
Reports on news and developments concerning pharmaceutical companies focusing on cancer treatment. Bioenvision's trials of breast cancer drug; Orphan drug status awarded to Allos Therapeutics breast cancer drug; U.S. Food and Drug Administration's (FDA) recommendation for wider use of Eli Lilly's Alimta; OSI Pharmaceuticals' submission of its cancer drug, Tarceva for FDA approval.
ACCESSION #
14388234

 

Related Articles

  • Cancer News Round-up.  // PharmaWatch: Cancer;September 2004, Vol. 3 Issue 9, p2 

    Reports on developments related to the pharmaceutical industry in the U.S. as of September 2004. Regulatory progress of Allos Therapeutics; Use of Eli Lilly's Alimta; Clinical trials of Bioenvision's Modrenal.

  • Cancer News Round-up.  // PharmaWatch: Cancer;July 2004, Vol. 3 Issue 7, p2 

    `Presents various news related to pharmaceutical treatment of cancer as of July 2004. First-line therapy metastatic breast cancer provided by expanded approval of Eli Lily's and Bristol-Myers Squibb's Gemzar/Taxol combination therapy; Fifty percent rise in Allos Therapeutics' stock price...

  • Tarceva Data Intensify Lung Cancer Competition.  // Bioworld Week;7/20/2009, Vol. 17 Issue 29, p3 

    The article reports that OSI Pharmaceuticals Inc., and partner Genentech Inc., have given a tough blow to their competitor Eli Lilly & Co. by announcing a drug for the treatment of lung cancer. As stated, the EGFR-inhibitor Tarceva (erlotinib) demonstrated a statistically significant overall...

  • Cancer News Round-up.  // PharmaWatch: Monthly Review;July 2004, Vol. 3 Issue 7, p4 

    Reports on the development in pharmaceutical industry as of July 2004. Expanded approval of the Eli Lilly's and Bristol-Myers Squibb's Gemzar/Taxol combination therapy; Rise of the stock price of Allos Therapeutics; Approval of Rituxan for several other lymphoma types.

  • Tarceva Survival Data Intensify Lung Cancer Maintenance Battle. Morrison, Trista // BioWorld Today;7/14/2009, Vol. 20 Issue 133, p1 

    The article reports on the competition for maintenance treatment of lung cancer, after the U.S. Food and Drug Administration (FDA) approved Eli Lilly & Co.'s chemotherapy drug Alimta. OSI Pharmaceuticals Inc. and Genentech Inc. have announced that Tarceva, an epidermal growth factor receptor...

  • Tarceva Survival Near Alimta, But EGFR Data Offer the Real Upside. Morrison, Trista // BioWorld Today;8/4/2009, Vol. 20 Issue 148, p1 

    The article reports on the presentation of new overall survival data for Tarceva, an epidermal growth factor receptor (EGFR)-inhibitor from OSI Pharmaceuticals Inc. and partner Genentech Inc./Roche AG for lung cancer maintenance, at the 2009 World Conference on Lung Cancer. The significant...

  • Key Cancer Announcements, May 15, 2004 -- June 14, 2004.  // PharmaWatch: Monthly Review;July 2004, Vol. 3 Issue 7, p4 

    Reports on the development in pharmaceutical industry in the U.S. as of July 2004. Expanded approval of the Eli Lilly's and Bristol-Myers Squibb's Gemzar/Taxol combination therapy to treat cancer; Improvement of the survival rates of patients taking Traceva; Declaration of disappointing results...

  • Breast Cancer News Headlines September 15, 2003--October 14, 2003.  // PharmaWatch: Cancer;November 2003, Vol. 2 Issue 11, p5 

    Reports on pharmaceutical developments related to breast cancer from September 15-October 14, 2003. Response rate of exemestane in breast cancer patients; Effectiveness of Aventis SA's taxotere injection concentrate in breast cancer treatment; Bioenvision Inc.'s research about Modrenal; Allos...

  • WORLD News & Analysis. Gopal, Kevin // Pharmaceutical Executive;Apr2001, Vol. 21 Issue 4, p32 

    Presents news on the pharmaceutical industry as of April 2001. Changes in the trade policies on health care affecting the industry; Number of pharmaceutical firms that submitted proposals to develop OSI-774, a compound for cancer treatment of OSI Pharmaceuticals; Growth in United States sales...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics